A Q&A with Jamie Clayton of Freeman Technology What is dynamic powder testing and why is it valuable for DPI development? Dynamic powder testing is a modern technique developed specifically to generate process relevant powder properties where dynamic powder properties, including basic flowability energy (BFE) and specific energy (SE), are generated from … [Read more...] about Using dynamic powder testing in DPI development
News
Hovione Technology acquires rights to the Papillon DPI
According to Hovione Technology, the company has acquired global development and commercialization rights to the Papillon multi-use dry powder inhaler from its inventor, Klaus-Dieter Beller. The blister-based DPI is reusable and formed from a single part, "enabling ultra-affordable drug therapies at global scale," the company said. The Papillon device will join … [Read more...] about Hovione Technology acquires rights to the Papillon DPI
Pulmatrix and Cip Tec enter into definitive agreement for Pulmazole
Following Pulmatrix's recent successful public offering, Pulmatrix and Cipla subsidiary Cipla Technologies (Cip Tec) have entered into a definitive agreement in which Cipla will acquire rights to the Pulmazole itraconazole DPI for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in asthma patients. The companies had previously announced terms of the … [Read more...] about Pulmatrix and Cip Tec enter into definitive agreement for Pulmazole
Cipla launches Niveoli MDI in India
Cipla Limited has announced the launch of its Niveoli extra-fine particle beclomethasone/formoterol fumarate MDI for the treatment of asthma and COPD in adults in India. Cipla India Business Head Nikhil Chopra commented, “Cipla is pleased to offer yet another milestone in respiratory inhalation therapy. Niveoli marks a first in acknowledging and addressing the issue … [Read more...] about Cipla launches Niveoli MDI in India
Insmed gets additional US patent for Arikayce inhalation suspension
Insmed Incorporated said that the U.S. Patent and Trademark Office (USPTO) has issued US patent No. 10,251,900, titled "Methods for treating pulmonary non-tuberculous mycobacterial infections," which is the 10th US patent covering the use of Arikayce amikacin liposome inhalation suspension for the treatment of Mycobacterium avium complex (MAC) lung disease. Arikayce … [Read more...] about Insmed gets additional US patent for Arikayce inhalation suspension
Synspira’s inhaled glycopolymer for CF gets orphan drug designation in EU
According to Synspira Therapeutics, the company's SNSP113 inhaled glycopolymer for the treatment of cystic fibrosis has received orphan drug desination from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP). The FDA granted orphan drug designation to SNSP113 in October 2018. The company said that it has received funding from … [Read more...] about Synspira’s inhaled glycopolymer for CF gets orphan drug designation in EU
Noveome Biotherapeutics raises $15 million for development of ST266
Noveome Biotherapeutics said that it has closed a $15 million Series D financing round that will help to fund further development of its ST266 biologic. Intranasal formulations of ST266 are in development for the treatment of optic nerve disease and for chronic traumatic encephalopathy (CTE). In 2017, Noveome announced positive data from a preclinical study of … [Read more...] about Noveome Biotherapeutics raises $15 million for development of ST266
Otitopic announces plans to develop its inhaled aspirin for the treatment of lung cancer
Otitopic, which recently announced that it received a new patent for the us of inhaled aspirin for the treatment of myocardial infarction, now says that it also plans to develop its Asprihale aspirin DPI for the treatment of lung cancer. The company cites published studies showing lower risk of lung cancer with aspirin use and the potential of aspirin to inhibit … [Read more...] about Otitopic announces plans to develop its inhaled aspirin for the treatment of lung cancer
Pulmatrix raises $16.6 million in public offering
Pulmatrix said that it has closed a public offering with expected gross proceeds of $16.6 million that will be used primarily for development of its inhaled therapies, especially Pulmazole inhaled itraconazole for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in asthma patients. The company had previously said that it expected to raise $14.4 … [Read more...] about Pulmatrix raises $16.6 million in public offering
NICE suggests patients use “greener” DPIs instead of MDIs
The UK's National Institute for Health Care and Excellence (NICE) has issued a new "patient decision aid" that emphasizes that a metered dose inhaler "contains propellant, so it has a higher carbon footprint than a DPI." In a statement, NICE explains, "Where several inhalers could be viable options, patients can opt for the more environmentally friendly option, which … [Read more...] about NICE suggests patients use “greener” DPIs instead of MDIs